A “minimalist” approach to transfemoral valve-in-valve transcatheter mitral valve replacement (TMVR), not unlike the approach commonly used with TAVI, appears to be safe and feasible when compared ...

SAN FRANCISCO -- Operators had a favorable early experience using the Tendyne transcatheter mitral valve replacement (TMVR) system for severe mitral regurgitation (MR) and mitral annular calcification ...

Please provide your email address to receive an email when new articles are posted on . A meta-analysis suggests reduced risk for stroke with anticoagulant use after transcatheter mitral valve repair.

Abbott Laboratories has received approval for a mitral valve replacement that can be implanted without open-heart surgery. The U.S. Food & Drug Administration gave the OK for the North Chicago-based ...

Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...

PHOENIX, AZ—Symptomatic patients with moderate-to-severe mitral regurgitation (MR) ineligible for surgery fare quite well with transapical (TA) transcatheter mitral valve replacement (TMVR), with more ...

Piedmont Heart Institute (PHI) physicians Pradeep K. Yadav, M.D., Director of Structural Interventions, and Vinod H. Thourani, M.D., Marcus Chairman of Cardiovascular Surgery, successfully performed ...

In this month alone, Edwards Lifesciences and Abbott have made deals with three mitral valve disease startups underscoring the possibility of a M&A flurry in this market. Arundhati Parmar Now that the ...

DENVER, CO — Two cardiac valve prostheses, similar in capability, offer the prospect of significant relief of mitral regurgitation (MR) via transcatheter mitral-valve replacement (TMVR) for patients ...

Patients undergoing transcatheter mitral valve replacement (TMVR) who receive direct oral anticoagulants (DOACs) have fewer bleeding and thrombotic events and shorter hospital stays than those taking ...

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid ...